JAK2 V617F Mutation ARMS-PCR Protocol

Introduction

The discovery of the JAK2 V617F mutation in 2005 reshaped how clinicians diagnose and manage MPNs [1,2]. Before this, MPNs were defined mostly by blood counts and bone marrow appearance. Today, a single molecular test can point straight to the disease in most patients.

This article walks through the principle behind ARMS-PCR for JAK2 V617F detection, the bench protocol step by step, and how to read the gel. We'll also place the test in its modern diagnostic context because while ARMS-PCR is excellent at telling you whether the mutation is there, quantitative methods are now standard for telling you how much is there [4].

JAK-STAT Signaling Pathway

JAK2 sits inside blood-forming cells as part of the JAK-STAT signaling pathway. Normally, cytokines like erythropoietin (EPO) and thrombopoietin (TPO) bind their receptors on the cell surface, JAK2 switches on briefly, and signals travel to the nucleus to make new red cells, platelets, or white cells. The mutation jams the switch in the "on" position — a classic gain-of-function change. The cell keeps producing blood cells whether or not it's being told to [1,2].

The result is one of the three classical Philadelphia-negative MPNs:

• Polycythemia vera (PV) — too many red cells; JAK2 V617F prevalence ~95–97% [1,3]
• Essential thrombocythemia (ET) — too many platelets; JAK2 V617F prevalence ~50–65%
• Primary myelofibrosis (PMF) — scarring of the bone marrow; JAK2 V617F prevalence ~50–65%

A positive JAK2 V617F test strongly supports an MPN diagnosis. In PV it's nearly universal and a major diagnostic criterion under the 2022 International Consensus Classification (ICC) and the WHO fifth edition [4,5].

What about JAK2 V617F-negative cases?

JAK2 V617F is the headline mutation, but it's not the only one. About 3–5% of PV patients carry JAK2 exon 12 mutations instead. In ET and PMF, CALR (calreticulin) mutations account for 20–35% of cases and MPL mutations for another 3–10%. Around 10% of ET and PMF cases are "triple-negative" where none of these drivers are present, and further testing is needed [4,5]. This matters because a negative JAK2 V617F result is the start of an investigation, not the end of one.

Principle of ARMS-PCR

ARMS stands for Amplification Refractory Mutation System. It's a clever twist on standard PCR that turns the polymerase into a mismatch detector.

The principle rests on one fact: DNA polymerase struggles to extend a primer when the very last base at the 3′ end doesn't match the template. So researchers design two primers:

1. A forward specific primer whose 3′ end perfectly matches the mutated JAK2 sequence (the T at position 1849).
2. A forward internal control primer that binds a separate region of JAK2 and amplifies regardless of mutation status.

If the mutation is present, the specific primer extends, and you get a mutant-allele band on the gel. If it's absent, the specific primer hits a mismatch and can't extend — no mutant band. The internal control band appears in every sample where the PCR worked, mutated or not. To sharpen specificity, an additional mismatch is often introduced a few bases from the 3′ end, which widens the melting-temperature gap between perfect matches and mismatches.

This dual-primer design is the basis for interpreting the gel. The two amplicons are deliberately sized differently so they resolve as separate bands.

Strengths

• Single-base discrimination. ARMS-PCR can reliably distinguish JAK2 V617F from wild-type, even though they differ by just one nucleotide.
• Clear visual readout. Bands on a gel with no specialized real-time equipment needed.
• Affordable and accessible. Works in most molecular labs.

Limitations

• Qualitative only. ARMS-PCR tells you the mutation is there but not how much. For monitoring treatment response, quantitative methods are needed [4,6].
• Primer design is fussy. Small errors can produce false positives or false negatives.
• Lower sensitivity than newer methods. Standard ARMS-PCR detects mutations at roughly 1–5% allele burden, while qPCR reaches ~0.1% and droplet digital PCR (ddPCR) ~0.01% [4,6]. The 2022 ICC explicitly recommends assays sensitive below 1% [4].
• Optimization required. Annealing temperature, MgCl₂, and primer concentrations all need tuning.

Where ARMS-PCR sits in modern diagnostics

ARMS-PCR remains a useful screening tool in resource-limited settings and teaching labs. In tertiary centers, it has largely been supplemented by real-time quantitative PCR (qPCR), droplet digital PCR (ddPCR), or next-generation sequencing (NGS) panels that detect JAK2 V617F alongside CALR, MPL, and other myeloid mutations in a single test [6]. Quantitative methods also let clinicians track allele burden over time, which correlates with thrombosis risk, splenomegaly, progression to myelofibrosis, and transformation to acute myeloid leukemia [3,6].

Method

This protocol is adapted from Baxter et al. (2005) [1]. The standard sample is peripheral blood DNA and bone marrow is not required.

Table 1. Primer sequences for JAK2 V617F mutation.

1. Wipe the PCR workbench and pipettes with alcohol spray. Turn on the UV light for 10 minutes before starting any work. Contamination is the single most common cause of false positives in this assay, so this step is non-negotiable.
2. Thaw samples and reagents by hand. Vortex briefly and spin down. Every component should be mixed and spun before pipetting.
3. Prepare the master mix in a 1.5 mL microcentrifuge tube on ice as shown in Table 2. 

Table 2. Preparation of Master Mix for PCR reaction.

4. Mix master mix gently and spin down using a microcentrifuge.
5. Add 20 µL of master mix to each respective PCR tube with pre-loaded 5 µL of template DNA on ice.
6. Always include a known positive control, a known negative (wild-type) control, and a no-template control on every run.
7. Set the cycling conditions in the PCR Thermal Cycler machine as shown in Table 3 and start the run. 

Table 3. Thermocycling conditions

7. Run the products on an agarose gel and visualize under UV. Proceed to interpretation.

Interpretation

The gel shows up to two bands per lane, and which bands appear tells you the mutation status.

• Internal control band only → wild-type sample. The PCR worked but no mutation was detected.
• Internal control band + mutant-allele band → JAK2 V617F mutation present.
• No internal control band → the PCR has failed. The result cannot be interpreted, regardless of whether a mutant band is visible. Repeat the reaction.

The internal control is the quality check. Without it, you cannot distinguish a true wild-type sample from a failed reaction.

Troubleshooting

PCR problems usually fall into one of five buckets. Work through them systematically before re-running.

Non-specific amplification (extra bands beyond the expected ones)

• Check primer design for degeneracy or unintended binding sites.
• Lower the primer concentration or raise the annealing temperature.
• Test for PCR inhibitors in the template DNA (heparin, hemoglobin, EDTA carryover).

No amplification at all (blank lane)

• Confirm DNA concentration with a NanoDrop or fluorometric assay.
• Check primer stocks for degradation; aliquot fresh working stocks.
• Verify MgCl₂ concentration and annealing temperature.

Faint bands

• Assess DNA integrity by gel electrophoresis. Degraded DNA amplifies poorly.
• Increase template input or extend the extension time.

Single band for both mutant and wild-type samples (no discrimination)

• The allele-specific primer isn't stringent enough. Re-verify the primer sequence and the position of the 3′ mismatch. Raise the annealing temperature.

Contamination (bands in the no-template control)

• Stop. Decontaminate the bench, pipettes, and reagents. Use fresh aliquots. Aerosol-resistant tips are essential.

A few habits prevent most of these problems: physically separate pre-PCR and post-PCR areas, never open a tube containing PCR product in the pre-PCR space, run controls on every plate, and aliquot reagents into single-use volumes.

How the Result Fits the Clinical Picture

A positive ARMS-PCR result is a strong pointer toward MPN, but it doesn't stand alone. The hematologist combines it with the complete blood count, bone marrow biopsy findings, and increasingly, a panel of mutations including CALR, MPL, and a broader myeloid NGS panel [4,5].

Quantitative allele burden (measured by qPCR or ddPCR, not ARMS-PCR) carries its own clinical weight. Higher burden tracks with higher risk of pruritus, splenomegaly, thrombosis, fibrotic progression, and AML transformation in PV [6]. It also serves as a biomarker for treatment response. Pegylated interferon-alpha can lower JAK2 V617F allele burden substantially, sometimes to undetectable levels [3]. JAK inhibitors for example ruxolitinib (approved 2011), fedratinib (2019), pacritinib (2022, for severe thrombocytopenia), and momelotinib (2023, for anemic myelofibrosis), generally reduce symptoms and spleen size without erasing the mutation [3,7].

This is why understanding the lab method matters: the test result is one input into a much larger clinical decision

Frequently Asked Questions (FAQs)

What is the JAK2 V617F mutation, and why does it matter?

JAK2 V617F is a single-letter change in the DNA of the JAK2 gene that swaps valine for phenylalanine at position 617 of the JAK2 protein. The mutation locks JAK2 into an always-on state, driving uncontrolled blood cell production. It's the most common mutation in Philadelphia-chromosome-negative myeloproliferative neoplasms, found in roughly 95–97% of polycythemia vera, 50–65% of essential thrombocythemia, and 50–65% of primary myelofibrosis cases.

How is JAK2 V617F detected in the lab?

Several methods exist. ARMS-PCR (allele-specific PCR) is a sensitive, qualitative test that uses a primer matching only the mutated sequence. An amplification on a gel means the mutation is present. Newer quantitative methods, including real-time quantitative PCR (qPCR) and droplet digital PCR (ddPCR), can measure the exact percentage of mutated DNA (the allele burden) and detect mutations down to 0.01%. The 2022 International Consensus Classification recommends assays sensitive below 1%.

Does a positive JAK2 V617F test confirm an MPN diagnosis?

No. A positive result strongly supports an MPN diagnosis but doesn't confirm it on its own. Diagnosis also requires a full blood count, bone marrow biopsy (in most cases), and assessment for other mutations such as CALR and MPL. A small number of people carry low-level JAK2 V617F clones without ever developing overt MPN and this is called clonal hematopoiesis.

What if JAK2 V617F is negative but the doctor still suspects MPN?

A negative result doesn't rule out MPN. In polycythemia vera, JAK2 exon 12 mutations account for most JAK2-negative cases. In essential thrombocythemia and primary myelofibrosis, CALR mutations occur in roughly 20–35% of cases, and MPL mutations in around 3–10%. Around 10% of ET and PMF cases are "triple-negative" where none of the three classical driver mutations are present. Further genetic testing is the next step.

Is JAK2 V617F inherited from parents?

No. JAK2 V617F is a somatic mutation, meaning it arises in body cells (specifically blood stem cells) during a person's lifetime. It is not present at conception and cannot be passed to children. The exact trigger isn't known, although it's thought to be a random error during stem cell division, with risk rising with age.

Can the JAK2 V617F mutation be cured or made undetectable?

For most patients, the mutation persists for life, but treatments can reduce the allele burden (the percentage of cells carrying it). Pegylated interferon-alpha has the best evidence for lowering JAK2 V617F allele burden, sometimes to undetectable levels. Allogeneic hematopoietic stem cell transplant can eliminate the mutation by replacing the patient's bone marrow with donor cells, but it carries serious risks and is reserved for high-risk myelofibrosis. JAK inhibitors like ruxolitinib control symptoms but generally do not erase the mutation.

Glossary of Related Medical Terms

• Allele — One of two or more versions of a gene at a given location on a chromosome. We inherit one allele from each parent.
• Allele burden (or variant allele frequency, VAF) — The percentage of DNA copies in a sample that carry the mutated version of a gene. A higher percentage usually means more of the patient's blood cells are clonal (cancerous).
• ARMS-PCR (Amplification Refractory Mutation System PCR) — A PCR method that uses primers designed to match only the mutated DNA sequence, so amplification happens only when the mutation is present.
• Constitutive activation — When a protein or pathway is permanently switched on, even without the normal trigger signal.
• Cytokine — A small signaling protein released by cells to regulate immunity, inflammation, and blood cell production. Erythropoietin and thrombopoietin are examples.
• Erythropoiesis — The production of red blood cells in the bone marrow.
• Exon — A coding portion of a gene that contributes to the final protein sequence. JAK2 has 25 exons; the V617F mutation lives in exon 14.
• Gain-of-function mutation — A genetic change that makes a protein more active than normal, instead of broken.
• Internal control (in PCR) — A separate DNA target amplified in the same reaction to confirm the PCR worked, even when no patient mutation is detected.
• JAK-STAT pathway — A signaling chain inside cells that turns external cytokine signals into instructions for the cell nucleus, driving blood cell production.
• Myeloproliferative neoplasm (MPN) — A group of blood cancers in which the bone marrow makes too many red blood cells, white blood cells, or platelets.
• Somatic mutation — A genetic change acquired during a person's lifetime in a body cell (not sperm or egg), so it cannot be passed to children.
• Thrombocythemia — An abnormally high platelet count.
• Thrombocytopenia — An abnormally low platelet count.
• Thrombosis — The formation of a blood clot inside a blood vessel.
• Wild-type — The normal, unmutated version of a gene.

Disclaimer: This protocol is for educational purposes only. Local laboratory standard operating procedures take precedence. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for clinical decision-making. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N., Green, A. R., & Cancer Genome Project (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (London, England), 365(9464), 1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9
2. James, C., Ugo, V., Le Couédic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., & Vainchenker, W. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434(7037), 1144–1148. https://doi.org/10.1038/nature03546
3. Tefferi, A., & Barbui, T. (2023). Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. American journal of hematology, 98(9), 1465–1487. https://doi.org/10.1002/ajh.27002
4. Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H. M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., Bueso-Ramos, C. E., Cortes, J. E., Dal Cin, P., DiNardo, C. D., Dombret, H., Duncavage, E. J., Ebert, B. L., Estey, E. H., Facchetti, F., Foucar, K., … Tefferi, A. (2022). International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200–1228. https://doi.org/10.1182/blood.2022015850
5. Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., Chen, W., Chen, X., Chng, W. J., Choi, J. K., Colmenero, I., Coupland, S. E., Cross, N. C. P., De Jong, D., Elghetany, M. T., Takahashi, E., … Hochhaus, A. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703–1719. https://doi.org/10.1038/s41375-022-01613-1
6. La Rocca, F., Grieco, V., Ruggieri, V., Zifarone, E., Villani, O., Zoppoli, P., Russi, S., Laurino, S., Falco, G., Calice, G., Marinaccio, A., Natalicchio, M. I., Albano, F., & Musto, P. (2020). Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study. Diagnostics (Basel, Switzerland), 10(3), 143. https://doi.org/10.3390/diagnostics10030143
7. Tefferi A. (2023). Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology, 98(5), 801–821. https://doi.org/10.1002/ajh.26857